Ticker

Bank of America Corp DE raised its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 33.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 111,736 shares of the biotechnology company's stock after acquiring an additional 28,078 shares during the period. Bank

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Bank of New York Mellon Corp acquired a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 565,666 shares of the biotechnology company's stock, valued at approximately $49,185,000. Bank of New York Mellon Corp owned approximately

BlackRock Inc. bought a new stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,432,023 shares of the biotechnology company's stock, valued at approximately $1,080,964,000. BlackRock Inc. owned about 11.50% of

Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.